And just like that, everyone stopped talking about Clascoterone? Research/Science 2/14/2026
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity This could be it!!! New treatment increase hair 500%
Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.
community OND-1 "Cyclosporine A” New hair loss treatment
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
community “Just minoxidil” users, how are you doing now?
Minoxidil alone is often insufficient for significant hair regrowth, with many users experiencing limited results or side effects, leading them to add finasteride or dutasteride for better outcomes. Some users report initial improvements with minoxidil but eventually require additional treatments to maintain or enhance hair growth.
community Clascoterone - what we have right now
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
community Currently Trending Twitter Post: Clascoterone Hailed as New Cure
Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.
Related Research
6 / 6 results
research ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES
This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.
research New drugs under investigation for the treatment of alopecias
This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.
research Androgenetic alopecia: An update
This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.
research Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments
Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
research Living Probiotic Microneedles Coordinate Antiandrogen and Nitric Oxide Therapy for Androgenetic Alopecia
In this study, researchers developed a probiotic-based microneedle system combining Weissella cibaria and clascoterone to target androgenetic alopecia, which in a mouse model improved hair density, vascular regeneration, and reduced inflammation, suggesting a promising treatment approach.
research Androgenetic Alopecia: Therapy Update
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.